PWG Business News: Your Gateway to Market Intelligence
PWG Business News is committed to providing real-time updates and expert-driven insights across various industries, including technology, healthcare, finance, energy, automotive, and consumer goods. We deliver carefully curated news, financial reports, and research-based updates, helping businesses and professionals stay informed and competitive in today’s dynamic business environment.
Our News section covers industry-shaping events such as market expansions, new product launches, mergers and acquisitions, policy shifts, and corporate earnings, offering a strategic advantage to decision-makers seeking actionable intelligence. By bridging industry leaders, stakeholders, and professionals with data-driven content, we empower our audience to navigate the complexities of the global market with confidence.
PWG Business News: Keeping You Ahead in the Business World
At PWG Business News, we deliver timely and credible business news, covering global market trends, economic shifts, and emerging opportunities. With comprehensive coverage spanning healthcare, technology, telecommunications, utilities, materials, chemicals, and financials, our platform provides accurate, well-researched insights that drive success for executives, investors, and industry professionals alike.
Whether you're tracking regulatory updates, innovation trends, or strategic collaborations, PWG Business News ensures you have access to high-quality, data-backed reports that enhance brand visibility, credibility, and engagement. Our mission is to keep you ahead by serving as your trusted source for impactful industry news and market intelligence.
Stay informed with PWG Business News – your gateway to the insights that shape the future of business.
Health Care
In a significant move to expand its offerings in the rapidly growing digital health market, Hims & Hers Health has announced the addition of Eli Lilly’s groundbreaking weight-loss drug, Zepbound, to its telehealth platform. This strategic decision not only strengthens Hims & Hers' position in the health and wellness sector but also underscores the evolving landscape of telehealth and obesity management. As of early April 2025, users of the platform can now access Zepbound, along with a generic version of Novo Nordisk’s diabetes medication, liraglutide, and other GLP-1 medications like Wegovy and Ozempic.
Hims & Hers Health, a multispecialty telehealth company, has been making waves in recent years by bridging gaps in access to medical care through digital channels. Founded with a focus on connectivity and personalized healthcare solutions, the company has grown into a leader in the online health and wellness space. By integrating weight loss medications like Zepbound into their service offerings, Hims & Hers is responding to the growing demand for effective and accessible solutions for obesity. This move comes on the heels of their successful launch of oral weight-loss programs and compounded GLP-1 medications, which have attracted over 200,000 new customers in the past year alone.
Zepbound, Eli Lilly’s branded form of tirzepatide, is a glucagon-like peptide-1 (GLP-1) receptor agonist that has garnered significant attention for its effectiveness in weight loss. It is available on Hims & Hers' platform at a premium price point of $1,899 per month. This contrasts with Lilly’s direct-to-consumer platform, LillyDirect, where self-paying customers can access Zepbound starting at $349 per month. For those with commercial insurance coverage, the cost on LillyDirect can be as low as $25.
| Medication | Hims & Hers Pricing | LillyDirect Pricing | |---------------------|----------------------|-----------------------------------------------------------| | Zepbound | $1,899 per month | Self-pay: $349/month; Insured: as low as $25 | | Mounjaro | $1,899 per month | Pricing not specified separately for Mounjaro | | Wegovy | $1,999 per month | Not listed on LillyDirect | | Ozempic | $1,799 per month | Not listed on LillyDirect | | Generic Liraglutide | $299 per month | Not listed on LillyDirect |
Hims & Hers' integration of these medications onto its platform signals a significant expansion in the way obesity treatments are delivered. By leveraging telehealth, the company aims to create a more holistic and accessible approach to weight loss, addressing both the medical and psychological aspects of managing weight.
Additionally, Hims & Hers plans to roll out personalized doses of semaglutide for patients who require them as part of their weight loss program, further emphasizing the company's focus on tailored healthcare solutions.
The inclusion of Zepbound and generic liraglutide on Hims & Hers' platform has sparked interest from investors and consumers alike. The company saw a 5% increase in stock value following the announcement, reflecting a growing confidence in the potential of the digital health sector. Hims & Hers expects significant revenue from its weight-loss services, projecting at least $725 million in 2025.
Despite the partnership in offering Zepbound, Eli Lilly has been keen to clarify that it has no official affiliation with Hims & Hers. The company emphasizes that Zepbound can be prescribed by any licensed healthcare professional, highlighting its availability and accessibility through various channels.
This development marks a pivotal moment for both Hims & Hers and the broader telehealth industry. As digital health platforms continue to play a more central role in delivering specialized medical care, companies like Hims & Hers are at the forefront of revolutionizing how patients access and utilize healthcare services.
In conclusion, Hims & Hers' move to integrate Eli Lilly’s Zepbound and other GLP-1 medications onto its telehealth platform represents a significant step forward in obesity management and pharmaceutical accessibility. As the digital health landscape continues to evolve, Hims & Hers is positioning itself as a leader in personalized healthcare solutions, offering a comprehensive approach to weight loss that combines medical treatments with the convenience of telehealth services.
